araag2/HINT huggingface dataset:
Clinical trial NCT00479934 (phase 2, status: completed)
Conditions: scleroderma, localized, scleroderma, systemic
ICD codes: L94.1, L94.0
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  More than 18 years old

          -  Documented diagnostic of scleroderma (systemic or cutaneous)

          -  Severe cutaneous sclerodermia or systemic sclerodermia with m-Rodnan score > 20/51

          -  Ejection fraction of more than 45 per cent at cardiac ultrasound pre-inclusion study

          -  Woman with efficient contraceptive method during trail treatment and during 3 month
             after the end of trial treatment

          -  All female patients with reproductive potential must have a negative pregnancy test
             (serum or urine) within the 7 days prior to enrolment

          -  Affiliated or profit patient of a social security system

          -  Signed informed consent

        Exclusion Criteria:

          -  new systemic treatment, potentially interfering with disease progression, beginning 3
             months prior the start trial treatment

          -  Patient with isolated cutaneous scleroderma treated with a drug potentially
             interfering with the course of the disease 4 weeks before starting the trial (Systemic
             corticosteroids, methotrexate, cyclophosphamide, bosentan)

          -  Scleroderma " en coup de sabre "

          -  Severe organ failure or anomaly of blood chemistry/hematology (bilirubin, SGOT, SGPT,
             creatinine > 1,5 ´ upper normal limit, polymorphonuclear granulocytes less than
             1*10*9/l or platelets less than 50*10*9/l),

          -  Ongoing cancer

          -  Ejection fraction ≤ 45 per cent at cardiac ultrasound pre inclusion study

          -  myocardial infarction of less than 6 mois at pre inclusion visit

          -  Non controlled chronic illness (diabetes, chronic kidney failure, chronic hepatitis,
             HIV infection),

          -  Major surgery less than two weeks before inclusion

          -  Pregnancy or lactation

          -  Absence of validated contraception in childbearing women.

          -  Contraindication to imatinib mesylate treatment as specified in product specifications

          -  Non observance anticipated and absence of informed consent
Clinical trial NCT00533637 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: cetirizine dihydrochloride (10 mg/ml) liposomal formulation, cetirizine dihydrochloride (10 mg/ml) buffer solution, placebo
SMILES: OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 to 50 years of age (inclusive)

          -  Body Mass Index (BMI) between 18 and 28 kg/m2

          -  History of pollen-induced seasonal allergic rhinitis for at least two years and
             otherwise healthy

          -  Elevated specific IgE to at least one aero allergen or at least one positive skin pick
             test (SPT)

          -  Seasonal allergic rhinitis with symptoms provoked by the allergen with a corresponding
             elevated specific IgE or positive SPT

          -  Signed written Informed Consent

        Exclusion Criteria:

          -  Perennial allergic rhinitis except for cat and/or dog sensitivity under the condition
             that these patients are not exposed to cats and dogs

          -  Soy bean allergy

          -  Peanut allergy

          -  Smoking during the last month before study inclusion

          -  Any upper respiratory tract infection during the period of 2 weeks before the start of
             the study

          -  Chronic medication

          -  Any medication, including herbal medicines, during their last five half-lives (t½)

          -  Nasal anatomical deviations

          -  Extensive use of nasal sprays as judged by the Investigator

          -  Ongoing nasal symptoms as judged by the Investigator

          -  Known hypersensitivity to cetirizine

          -  Pregnant or breast-feeding women

          -  Fertile women not using reliable methods of contraception (i.e. IUD, barrier method,
             hormonal contraceptives, abstinence)

          -  Participation in any other investigational study in the last three months

          -  Inability to adhere to the study plan

          -  Previous inclusion in this study

          -  Blood donation during the last three months
Clinical trial NCT00191412 (phase 2, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of cancer of the liver which is metastatic or locally recurrent and not
             amendable to curative therapy.

          -  Patient must have measurable disease

          -  Patient may have received prior arterial chemoembolization, completed 8 weeks prior to
             study enrollment, but no other previous chemotherapy

          -  Prior radiation is permitted, but must be completed at least 2 weeks prior to study
             enrollment.

          -  Prior central nervous system metastases are acceptable if the patient has received
             radiation ot the brain, is not on steroids, and does not have related symptoms.

        Exclusion Criteria:

          -  Patients who have had prior therapy with Pemetrexed.

          -  Patients with a history of other invasive malignancies, with the exception of
             non-melanoma skin cancer, are excluded if there is any evidence of other malignancy
             being present within the last five years. Patients are also excluded if their previous
             cancer treatment contraindicates this protocol therapy.

          -  Patients who have received radiation to more than 25% of marrow
Clinical trial NCT01074008 (phase 2, status: completed)
Conditions: hepatitis c, hcv, chronic hepatitis c infection, hepatitis c genotype 1
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450, abt-072, abt-333, ritonavir, peginterferon alpha-2a, ribavirin
SMILES: [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis C virus (HCV), genotype 1 infection (HCV ribonucleic acid level
             greater than or equal to 100,000 IU/mL) at screening

          -  Liver biopsy within 3 years with histology consistent with HCV-induced liver damage,
             with no evidence of cirrhosis or liver pathology due to any cause other than chronic
             HCV

          -  Treatment naïve male or female between the ages of 18 and 65

          -  Females must be post-menopausal for more than 2 years or surgically sterile

          -  Negative screen for drugs and alcohol

          -  Negative hepatitis B surface antigen (HBsAg) and anti-human immunodeficiency virus
             antibodies (anti-HIV Ab)

          -  No use of cytochrome P450 3A (CYP3A) and cytochrome P450 2C8 (CYP2C8) enzyme inducers
             or inhibitors within 1 month of dosing

          -  Be in a condition of general good health, as perceived by the investigator, other than
             HCV infection

        Exclusion Criteria:

          -  Significant sensitivity to any drug

          -  Use of herbal supplements within 2 weeks prior to study drug dosing

          -  History of major depression within 2 years

          -  Prior treatment with any investigational or commercially available anti-HCV agents

          -  Abnormal laboratory tests
Clinical trial NCT00466440 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: enzastaurin, placebo, docetaxel, prednisone
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  You are at least 18 years old.

          -  You live close enough to the doctor's office to attend all of your required visits.

          -  You have not been treated with chemotherapy for your prostate cancer.

          -  Your organs must be functioning properly.

        Exclusion Criteria:

          -  You are unable to swallow pills.

          -  You have another serious illness besides your prostate cancer.

          -  You have taken another experimental drug within the last 30 days.

          -  You have a serious heart condition.

          -  You are receiving another anti-cancer therapy.
Clinical trial NCT02079519 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    the study was discontinued prematurely by the sponsor due to a lack of recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, 19-75 years of age

          -  Multiple myeloma.

          -  Progressive disease after at least 2 lines of prior therapy.

        Exclusion Criteria:

          -  Non-secretory myeloma.

          -  History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer
             in situ of the cervix within the last 5 years.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start.

          -  Clinically significant cardiac disease.
Clinical trial NCT01531712 (phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine, tarceva, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to a low recruitment rate since start of recruitment period.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Before the beginning of the specific protocol procedures must be obtained and
             documented a written consent form. Patients must have sufficient capacity to
             understand and sign the consent form.

          -  Exocrine pancreatic potentially resectable carcinoma, histologically confirmed.

          -  Aged 18-75 years.

          -  OMS functional state (FE) from 0-2 and Karnofsky functional state 70%.

          -  Radiologically or measurable disease, defined as borderline resectability disease.

          -  Appropriate biological parameters: neutrophils > 1.500/mL; platelets > 100.000/mL;
             hemoglobin > 10 g/dl.Serum creatinine < 1,5 x upper limit of normal (LSN); alkaline
             phosphatase < 3 x LSN and bilirubin < 1,5 x LSN; AST and ALT 2,5 x LSN.

          -  Controlled biliary obstruction in all the patients before their inclusion in the
             study.

          -  Absence of peripheral neuropathy grade 2.

          -  Life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Previous administration of chemotherapy, radiotherapy or any investigational agents
             for pancreatic cancer treatment.

          -  Administration of other experimental treatment during this study or in the previous 6
             months.

          -  Pregnancy, inappropriate or unsafe use of contraceptive methods or women who are
             breast-feeding.

          -  Clinically significant heart disease(for example: congestive heart failure,
             symptomatic coronary artery disease and cardiac arrhythmias not properly controlled
             with medication or myocardial infarction in the last 12 months).

          -  Presence of significant ophthalmologic anomaly, included: severe dry eye syndrome,
             Sjogren syndrome, dry keratoconjunctivitis, severe exposure keratopathy, conditions
             that might increase the risk of epithelium complications.

          -  Patients with lack of physical integrity of the upper gastrointestinal tract or bad
             absorption syndromes or unable to ingest the tablets.

          -  Other previous bad or concurrent diseases, with the exception of nonmelanoma skin
             cancer.

          -  Medical or psychiatric pathologies that are severe or uncontrolled.

          -  Distant metastases.
Clinical trial NCT01189812 (phase 2, status: completed)
Conditions: major depressive disorder, dysthymia, depression not otherwise specified, borderline personality disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F60.3
Drugs: lithium carbonate, placebo, citalopram
SMILES: [Li+], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  18-75 years of age

          -  Meets criteria for Major Depressive Disorder, Dysthymia, Depression Not Otherwise
             Specified or Borderline Personality Disorder

          -  Ability to speak, read and understand the English Language and provide written
             informed consent

        Exclusion Criteria:

          -  Current, unstable and significant medical condition or illness

          -  History of Thyroid disorder, seizure disorder, tumors or other CNS condition that
             predisposes the patient to risk of seizure

          -  Pregnant or lactating females

          -  Abnormal clinical laboratory test results

          -  Intolerance or hypersensitivity to SSRIs or lithium

          -  History or current diagnosis of bipolar mood disorder, psychosis, schizophrenia or
             dementia

          -  Certain mediations my not be used prior or during the study
Clinical trial NCT01681121 (phase 2, status: completed)
Conditions: narcolepsy
ICD codes: G47.411, G47.419, G47.421, G47.429
Drugs: adx-n05, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of narcolepsy

          -  Good general health

          -  Willing and able to comply with the study design and schedule and other requirements

        Exclusion Criteria:

          -  If female, pregnant or lactating

          -  Customary bedtime later than midnight

          -  History of significant medical condition, behavioral, or psychiatric disorder
             (including suicidal ideation), or surgical history

          -  Any other clinically relevant medical, behavioral or psychiatric disorder other than
             narcolepsy that is associated with excessive sleepiness

          -  History of significant cardiovascular disease

          -  Body mass index > 34

          -  Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day

          -  History of alcohol or drug abuse within the past 2 years

          -  Nicotine dependence that has an effect on sleep
Clinical trial NCT00614705 (phase 2, status: completed)
Conditions: neuralgia, postherpetic
ICD codes: B02.22
Drugs: ph-797804, placebo
SMILES: CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, at least 18 years of age

          -  Patients must have pain present for more than 3 months after healing of the Herpes
             zoster skin rash. There is no upper limit on the duration of PHN.

          -  Patients at screening visit (V1) must have a score ≥40 mm on the Pain Visual Analog
             Score (VAS).

        Exclusion Criteria:

          -  Patients having other severe pain, which may impair the self-assessment of the pain
             due to post-herpetic neuralgia

          -  History within the previous year of: myocardial infarction, cardiac arrhythmia (e.g.
             atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, supraventricular
             tachycardia, ventricular tachycardia), left ventricular failure, New York Heart
             Association (NYHA) Class III-IV congestive heart failure requiring treatment, unstable
             angina, coronary angioplasty, coronary artery bypass grafting (CABG) or
             cerebrovascular accident (including transient ischemic attacks).

          -  Tuberculosis without treatment and/or positive tuberculin reaction to PPD (Purified
             Protein Derivative) without known (documented) vaccination with the bacilli
             Calmette-Guerin vaccine (BCG).

          -  A positive approved immunoassay/ELISA blood test for TB (e.g. TB T-SPOT™,
             QuantiFERON-Gold

          -  Any clinically significant skin lesions as described in Common Terminology Criteria
             for Adverse Events for Dermatology (CTCAE) Version 3.0

          -  ECG abnormalities at screening or randomization

          -  Evidence of organ dysfunction or hematopoietic disorder
Clinical trial NCT00193037 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: liposomal doxorubicin, docetaxel
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Metastatic breast cancer confirmed by biopsy

          -  Prior adjuvant/neoadjuvant treatment allowed

          -  Measurable disease

          -  Able to perform activities of daily living with minimal assistance

          -  Age 18 years or older

          -  Adequate bone marrow, liver and kidney function

          -  Normal heart function

          -  Written informed consent

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Pre-existing moderate peripheral neuropathy

          -  History of significant heart disease

          -  Meningeal metastases.

          -  Prior chemotherapy for metastatic breast cancer

          -  No measurable disease (including bone only, pleural effusions, etc.)

          -  Receiving Herceptin therapy.

          -  Women who are pregnant or lactating.

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT01353248 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: gs-5885, tegobuvir, gs-9451, ribavirin tablet, gs-5885
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, FC1=CC=CC=C1C1=NC2=CN(CC3=CC=C(N=N3)C3=CC=C(C=C3C(F)(F)F)C(F)(F)F)C=CC2=N1, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@@H]2C[C@@H]2C1)C(C)(C)C)OC1=C2C=CC(OCCN3CCOCC3)=C(Cl)C2=NC(=C1)C1=CSC(NC(C)C)=N1)C(O)=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects 18 to 70 years of age

          -  Chronic HCV infection for at least 6 months prior to Baseline (Day 1)

          -  Liver biopsy results (performed no more than 2 years prior to Screening) indicating
             the absence of cirrhosis

          -  Monoinfection with HCV genotype 1a or 1b

          -  HCV treatment-naïve

          -  Body mass index (BMI) between 18 and 36 kg/m2

          -  Creatinine clearance ≥ 50 mL/min

          -  Subject agrees to use highly effective contraception methods if female of childbearing
             potential or sexually active male.

          -  Screening laboratory values within defined thresholds

        Exclusion Criteria:

          -  Autoimmune disease

          -  Decompensated liver disease or cirrhosis

          -  Poorly controlled diabetes mellitus

          -  Severe psychiatric illness

          -  Severe chronic obstructive pulmonary disease (COPD)

          -  Serological evidence of co-infection with human immunodeficiency virus (HIV),
             hepatitis B virus (HBV), or another HCV genotype

          -  Suspicion of hepatocellular carcinoma or other malignancy (with exception of certain
             skin cancers)

          -  History of hemoglobinopathy

          -  Known retinal disease

          -  Subjects who are immunosuppressed

          -  Subjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine,
             heroin), methadone, or ongoing alcohol abuse

          -  Subjects must have no history of clinically significant cardiac disease, including a
             family history of Long QT syndrome, and no relevant electrocardiogram (ECG)
             abnormalities at screening